ArticleBMC gastroenterology2026
Development and validation of a deep learning radiomics model based on ultrasound and clinical features to predict prognosis in elderly patients with advanced pancreatic cancer after HIFU therapy.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThis study aimed to construct an artificial intelligence model based on ultrasound radiomics and deep learning, integrating clinical features to develop a fusion model for individualized prediction of survival outcomes in elderly patients with advanced pancreatic cancer receiving high-intensity focused ultrasound (HIFU) treatment.
methodsThis retrospective study enrolled elderly patients with advanced pancreatic cancer admitted to Huadong Hospital Affiliated to Fudan University from March 2015 to March 2024, randomly divided into training and validation cohorts in a 7:3 ratio. Patients were categorized into four groups based on treatment modality: HIFU alone, HIFU combined with 125I seed implantation, HIFU combined with chemotherapy, and triple therapy (HIFU + 125I + chemotherapy). Traditional radiomics features and deep learning features based on the ResNet architecture were extracted from pre-treatment ultrasound images. After rigorous feature selection, clinical, radiomics, deep learning, and multi-modal fusion Cox proportional hazards models were constructed. Predictive performance for overall survival and clinical utility were evaluated comprehensively.
resultsThis study included 250 elderly pancreatic cancer patients. Multivariate analysis identified liver metastasis, TNM stage, body weight, number of HIFU sessions, and treatment regimen as independent prognostic factors (all p < 0.05). Predictive models were constructed using selected clinical features, traditional radiomics and deep learning features from ultrasound images. The deep learning radiomics model demonstrated the highest C-indices in both the training and validation sets (0.735 and 0.716, respectively), outperforming the clinical model (0.664, 0.633) and the traditional radiomics model (0.658, 0.592). The combined model, integrating clinical and deep learning features, achieved the best predictive performance, with C-indices of 0.748 (training) and 0.739 (validation). Time-dependent ROC analysis further confirmed that the combined model maintained the highest AUC values for 1-year and 1.5-year survival prediction in the validation set (0.819 and 0.884, respectively), significantly enhancing the accuracy and generalizability of survival stratification.
conclusionsThe ultrasound-based deep learning radiomics model demonstrated favorable performance in predicting the prognosis of elderly pancreatic cancer patients undergoing HIFU treatment, with performance superior to traditional clinical and radiomics indicators. It can facilitate more accurate individualized survival risk stratification, providing a potentially useful tool for precise treatment decision-making in advanced pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.